FDA Grants Breakthrough Device Designation To SeaStar Medical's Selective Cytopheretic Device For Cardiorenal Syndrome
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted Breakthrough Device Designation to SeaStar Medical's Selective Cytopheretic Device for Cardiorenal Syndrome. This designation will expedite the development and review process of the device, potentially leading to faster market entry.
September 29, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SeaStar Medical's device receiving FDA's Breakthrough Device Designation could potentially lead to increased demand for ICU's products and services, as the device is expected to expedite the treatment process for Cardiorenal Syndrome.
The FDA's Breakthrough Device Designation for SeaStar Medical's device could potentially lead to faster market entry and increased demand for related products and services. As ICU is mentioned in the context, it's likely that their products or services could be positively impacted by this development.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50